|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Head and Neck Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Carcinoma | |||||
| Carcinoma, Squamous Cell | |||||
| Head and Neck Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Neoplasms, Squamous Cell | |||||
| 4 | Interventions listed in this trial | ||||
| Erlotinib | |||||
| Docetaxel | |||||
| Radiation Therapy | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Protein Kinase Inhibitors | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| M.D. Anderson Cancer Center | |||||
| Aventis Pharmaceuticals | |||||
| Genentech | |||||